Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. & Notice of 2021 Final Results.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

The Cannigma

FEBRUARY 2, 2021

“Medical cannabis was legally approved in Germany in 2017 when approval was given for therapy-resistant symptoms in severely affected patients independent of diagnosis and without clinical evidence-based data,” lead investigator Professor Carsten Buhmann of the University Medical Center Hamburg-Eppendorf explained in a statement.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Otherside Farms

JANUARY 25, 2019

Scientists hope to perform human trials in the near future. Researchers at the University of Nottingham conducted a meta-analysis of previous studies, reports the Nottingham Post, concluding that cannabinoids could reduce the severity of stroke as well as improve neurological outcomes.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Cannabis Law Report

JULY 8, 2021

Seeks To Identify Novel Cannabinoids For Therapeutic Use. The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids. CHARLOTTE, N.C.–(BUSINESS

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

The Cannigma

DECEMBER 14, 2021

Hexahydrocannabinol (HHC), which was patented in the late 1940s as a “therapeutic substance having marihuana activity,” is a cannabinoid that’s growing in popularity and availability. Hydrogenation of THC isomers such as delta-9-THC or delta-8-THC results in the formation of hexahydrocannabinol (HHC), a hydrogenated cannabinoid.

Research and Development 116

Research and Development Cannabinoids Clinical Trials THC 116

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “We

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. We could potentially develop north of 11,000 drugs that are cannabinoid-based. This means that U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

JUNE 10, 2021

The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Because THC presence is an imperfect proxy for impairment [ 10 ], driving data may be limited in clarifying what traffic safety risks, if any, are associated with permissive marijuana policies.

Policy 59

Policy Safety Marijuana Data 59

Cannabis Law Report

SEPTEMBER 20, 2021

The products leverage pharmaceutical technology to maximize performance and safety. CB4 products are formulated based on the latest medical evidence and come in convenient dosage forms that deliver effective levels of cannabinoids. Opticann medical cannabis products merge cannabis medicine with modern medicine.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

The Joint Blog

JANUARY 23, 2020

.” For this study, “The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted.” One isolated study indicates some potential efficacy for an oral cannabinoid /terpene combination in ADHD.

Clinical Trials 52

Clinical Trials Sleep Marijuana Cannabinoids 52

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Forward-looking statements.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Veriheal

JANUARY 5, 2023

A randomized, double-blind, cross-over trial of cannabis recently published by Research Gate explored whether or not cannabidiol (CBD) — the primary non-intoxicating constituent of cannabis and hemp — improves or reduces the cannabis safety. . About the Study Into CBD’s Influence on Cannabis Safety. Senate approval.

Clinical Trials 82

Clinical Trials Safety Consumption CBD 82

TheAnswerPage

JANUARY 11, 2022

and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ In addition, if clinicians are not well informed about the health effects of cannabinoid-based products, clinicians will not be able to optimally treat their patients. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Clinical Trials and Human Subject Protections. Here are the top five considerations: 1.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

FEBRUARY 15, 2019

Mr Shanmugam said this just before a joint statement by the Home Affairs and Health ministries which set out the government’s position the use of pharmaceutical products containing cannabinoids. On the other hand, they found that are some medicine with cannabinoid products that are scientifically researched and medically approved.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

Veriheal

AUGUST 31, 2020

Data shows that Hispanic Americans are more interested in using cannabis and CBD for wellness than other groups and “is believed to be in part due to the connections between the Hispanic community and nature.” Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease. March 31, 2021. ($). .

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

The Joint Blog

APRIL 17, 2020

Over the past few decades, there has been an increased interest in leveraging cannabis and cannabinoids for medicinal purpose. Reported adverse effect in many clinical trials included amnesia, impaired balance, disturbed attention, dizziness, lethargy, and somnolence.

Events 48

Events THC Chronic Pain Sleep 48

The Joint Blog

JULY 25, 2020

Out of all the cannabinoids, CBD from hemp is the most widely used for manufacturing cannabis-derived products such as oils, tinctures, candies, and even cosmetics because it carries almost no THC – the compound that gives marijuana its mind-altering properties. CBD Legal and Safety Issues An FDA report presented to the U.S.

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

SEPTEMBER 24, 2019

Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the “high” associated with cannabis. The approval of cannabidiol oral solution is based on results from four randomised, controlled Phase 3 trials. LONDON and CARLSBAD, Calif., In June 2018 GW, along with its U.S.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JULY 23, 2019

After using Koi’s products, Thurston was given a random drug test by her employer, which came back positive for cannabinoids. It is important that they conduct medical research into the safety and effectiveness of cannabis products through adequate and well-controlled clinical trials. She lost her job as a result.

Law 40

Law Clinical Trials CBD Edibles 40

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

The Cannigma

JANUARY 13, 2023

A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. Chemovars classify cannabis based on the dominant cannabinoid, and there are three main types on the market right now. headaches per month.

Terpenes 132

Terpenes Strains THC Treatment 132

The Cannigma

APRIL 8, 2021

Yeah, there are thousands of strains, but those thousands of strains, but those thousands of strains only make let’s say one or two of 60 cannabinoids in abundance. Half of those cannabinoids of plant doesn’t make or three quarters because they’re byproducts. This is by nature of the way we consume cannabinoids.

Medicine 108

Medicine Cannabinoids Cannabis THC 108

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

MAY 13, 2019

Screening for relevancy, full-text review, data extraction, and risk of bias were completed by two independent investigators. Data Availability: All relevant data are within the paper and its Supporting Information files. Pre-defined inclusion and exclusion criteria were applied uniformly.

Medicine 45

Medicine Research and Development Clinical Trials Data 45

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Data collection. 2016 ; Sznitman et al.

Research and Development 52

Research and Development Medicine Access Media 52

The Cannigma

FEBRUARY 1, 2023

Even if a cannabinoid has shown promise on one cancer line, that doesn’t mean it will work for all cancers – even if it’s within the same organ system. Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

OCTOBER 29, 2019

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.

Safety 45

Safety CBD Clinical Trials Oil 45